Recruiting

New Drug Combination Versus Standard Treatment for Recurring Lymphoma

Plain-English translation of NCT05180097 on ClinicalTrials.gov ↗ · Source last updated February 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial tests whether a new combination of two drugs called and works better than the current standard treatment (a three-drug chemotherapy called GDP) for people with Hodgkin lymphoma that has come back or stopped responding to previous treatment. You would receive one of these two treatments, followed by high-dose chemotherapy and a stem cell transplant to help rebuild your blood system.

The standard three-drug treatment can help some patients, but doctors want to know if this new two-drug combination might work better, cause fewer side effects, or help more people with this difficult-to-treat form of lymphoma.

Do you qualify?

You likely qualify if…

you have been diagnosed with classical Hodgkin lymphoma that has returned or is not responding to treatment
your previous treatment included anthracycline-containing chemotherapy (a standard first-line therapy)
you are at least 18 years old
you are healthy enough to tolerate high-dose chemotherapy and stem cell transplant (performance status 0-1)
your blood counts, kidney function, and liver function are acceptable for treatment
you are willing and able to complete quality-of-life questionnaires during the study

You likely don't qualify if…

you have already received salvage chemotherapy (rescue treatment) for your relapsed or refractory disease
you have significant nerve damage or severe shortness of breath from previous treatments
you have a history of other cancers (with limited exceptions for skin cancer or very old cancers)
you have an active immune system disorder or are taking immunosuppressive medications
you are unable to have a biopsy sample taken or released for research testing

What participation looks like

You will be randomly assigned to receive either the new two-drug treatment ( and ) or the standard three-drug chemotherapy (GDP). After completing your assigned chemotherapy, both groups will then receive high-dose chemotherapy followed by a stem cell transplant. You will have regular clinic visits for treatment, blood tests, and imaging scans to monitor how well the treatment is working. The study team will also ask you to complete questionnaires about your quality of life at different points in the trial.

AI-generated summary from trial data · Jun 9, 2026 · Not medical advice

Trial locations(18 sites)

Australia

Concord Repatriation General Hospital, Concord, New South Wales

Shoalhaven Cancer Care Centre, Nowra, New South Wales

Wollongong Hospital, Wollongong, New South Wales

Royal Adelaide Hospital, Adelaide, South Australia

Austin Hospital, Heidelberg, Victoria